A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma

Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides

(2012) P. Filipazzi et al.   CLINICAL CANCER RESEARCH

Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy

(2010) Yann Godet et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: Comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression

(2010) Véronique Decot et al.   EXPERIMENTAL HEMATOLOGY

Treatment of Metastatic Melanoma with Autologous Melan-A/Mart-1-Specific Cytotoxic T Lymphocyte Clones

(2009) Amir Khammari et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

CD25 Blockade protects T Cells from Activation-induced Cell Death (AICD) via Maintenance of TOSO Expression

(2009) G. H. S. Richter et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes

(2008) Régis Bouquié et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency

(2008) Yann Godet et al.   JOURNAL OF EXPERIMENTAL MEDICINE